Albany NY, United States: Pancreatic cancer is characterized by the uncontrolled growth of cells, i.e., malignant cells in the tissues of the pancreas.
Albany NY, United States: Pancreatic cancer is characterized by the uncontrolled growth of cells, i.e., malignant cells in the tissues of the pancreas. The malignant cells lead to the formation of tumors in the pancreas which deters the normal functioning of the organ.
Read Report Overview - https://www.transparencymarketresearch.com/pancreatic-cancer-therapeutics-market.html
Pancreatic cancer is a key challenge in the U.S. with presence of the highest number of pancreatic cancer patients in the world. It is estimated that in the country, 53,670 new cases of pancreatic cancer are likely to be diagnosed in 2017. Patients with pancreatic cancer have the lowest survival rate of all cancers. Over the last 40 years, survival has improved for most of the cancers but not for pancreatic cancer. This cancer is the third leading cause of cancer-related death in the U.S., surpassing breast cancer, in 2016.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=31349
Factors such as high unmet therapy needs in the overall oncology market, rising concerns across the world, and new developments in this field of treatment are contributing to the growth of the global pancreatic cancer therapeutics market. However, technologies for the timely diagnosis of this cancer type are yet to develop fully. Hence, a majority of pancreatic cancer patients are being diagnosed at an advanced stage of the disease. In the advanced stage of this cancer type, the treatment options are less, resulting in high mortality rates. These factors are limiting the growth of the market for pancreatic cancer therapeutics. Estimates show that only a small percentage (about 12% to 15%) of patients is diagnosed early enough to be treated with surgical procedures, drugs, and chemotherapy.
Request for Analysis of COVID-19 Impact on Pancreatic Cancer Therapeutics Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=31349
Pancreatic cancer occurs in exocrine cells which produce digestive juices or endocrine cells that secrets hormones regulating blood sugars. The global pancreatic cancer therapeutics market is segmented based on whether the cancer affects endocrine or exocrine functions. Adenocarcinoma, which constitutes nearly 95% of all exocrine pancreatic cancers, is the most common pancreatic cancer type. Other prevalent cancers of the pancreas include pancreatic neuroendocrine tumors (NETs), gastrinoma (Zollinger-Ellison syndrome), glucagonoma, insulinoma, VIPoma (Verner-Morrison syndrome), and multiple endocrine neoplasia type-1 (MEN1). In terms of treatment, the pancreatic cancer therapeutics market is segmented into surgery, chemotherapy, radiation therapy, and targeted therapy. The treatment of this cancer type often consists of a combination of radiation, chemotherapy, and targeted therapy.
Geographically, the market for pancreatic cancer therapeutics is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Investment in research and development growing prevalence and increasing reach of novel techniques in the developing regions are the factors expected to drive the growth in these regions during the forecast period.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=31349
The pancreatic cancer therapeutics market is dominated by Gemzar (Gemcitabine) developed by Eli Lilly. Gemzar is indicated as first-line treatment of nonresectable (stage II or stage III) or metastatic (stage IV) adenocarcinoma of the pancreas. Gemzar and Tarceva (Erlotinib) by Genentech/OSI Pharmaceuticals/Roche account for a majority share of the global pancreatic cancer therapeutics market as these drugs have been in the market for a considerable time.
Pre Book Pancreatic Cancer Therapeutics Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=31349<ype=S
Abraxane by Celgene is another therapeutic drug that was launched in the U.S. and Europe in 2013 and 2014, respectively. Abraxane was the first drug to be approved for the pancreatic cancer treatment in almost a decade, and it is aggressively competing with existing drugs. A few pipeline drugs are expected to be launched toward the end of the forecast period. Numerous untapped opportunities in clinical development exist in the pancreatic cancer therapeutics market.
Major players operating in the market include Amgen, Inc., Genentech, Inc., Abraxis BioScience, LLC (Celgene Corporation), Pfizer Inc, Eli Lilly and Company, Novartis AG, and Threshold Pharmaceutic.
More Trending Reports by Transparency Market Research:
Exosome Technologies Market The outbreak of severe acute respiratory syndrome β-coronavirus 2 (SARS-CoV-2) has led to a potential long-lasting global health crisis. Thus, extracellular vesicles (EVs) are emerging as a possible solution for improving lung immunity. Companies in the exosome technologies market are increasing their research for conducting the pathogenesis of various lung diseases and viral infections in order to keep economies running during the COVID-19 outbreak.
Value-based Healthcare Services Market The COVID-19 pandemic is posing a huge challenge to the whole world since 2020. This infection leads to multiple organ failure, pneumonia, severe and acute respiratory disorders and in severe cases, death. COVID-19 has prompted the launch and modification of care delivery to more virtual models. It also has proven the high value of remote monitoring. Providers are monitoring patients’ health status and behaviors via devices and wireless apps more often, instead of visiting the office.
Healthcare 3D Printing Market The increasing adoption of 3D printing technologies will bring exponential growth for the healthcare 3D printing market. The demand for 3D technologies across fracture patients, cancer patients, and skull-based tumors will bring tremendous growth opportunities for the healthcare 3D printing market.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453